- Title
- The rationale of dose-response curves in selecting cancer drug dosing
- Creator
- Martin, Jennifer H.; Dimmitt, Simon
- Relation
- British Journal of Clinical Pharmacology Vol. 85, Issue 10, p. 2198-2204
- Publisher Link
- http://dx.doi.org/10.1111/bcp.13979
- Publisher
- Wiley-Blackwell Publishing
- Resource Type
- journal article
- Date
- 2019
- Description
- Drug development for cancer chemotherapy has an interesting history. A mix of serendipity, animal, cell line, and standard pharmacological principles of dose, dose-response, dose-concentration, dose intensity and combination therapies have been used to develop optimal dosing schedules. However in practice, significant gaps in the translation of preclinical to clinical dosing schedules persist, and clinical development has instead moved to new drug development. A older chemotherapies are still the backbone of most solid tumour schedules, therapeutic drug monitoring has emerged as a method for optimising the dose for individual patients.
- Subject
- body surface area; cancer; dose–response; flat dosing; log‐dose; surrogate outcome
- Identifier
- http://hdl.handle.net/1959.13/1417522
- Identifier
- uon:37220
- Identifier
- ISSN:0306-5251
- Rights
- This is the peer reviewed version of the following article: Martin, JH, Dimmitt, S. The rationale of dose–response curves in selecting cancer drug dosing. Br J Clin Pharmacol. 2019; 85: 2198– 2204. https://doi.org/10.1111/bcp.13979. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
- Language
- eng
- Full Text
- Reviewed
- Hits: 1187
- Visitors: 1339
- Downloads: 164
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Author final version | 674 KB | Adobe Acrobat PDF | View Details Download |